# Orgenesis (ORGS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ORGS
## Company Profile
- Ticker: ORGS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.4124 USD
- Market cap: Not available USD
- Last updated: 2026-09-08
## Business Overview
Orgenesis is a cell-therapy and advanced-manufacturing company focused on decentralized manufacturing, point-of-care cell processing, and enabling infrastructure for regenerative medicine. Its story blends therapeutic ambition with platform and services capability.
## Why The Stock Is Moving

As of Sep 8, 2026, ORGS closed up 1161.2% at $0.4124. No new same-company headline was identified in the current news window.

## Geographic Base

Orgenesis is headquartered in the United States and listed on NASDAQ, with a global and platform-oriented biotech profile. It sits between cell therapy, manufacturing services, and biotech infrastructure.

## Business Model

The business model depends on platform partnerships, manufacturing solutions, and the ability to commercialize decentralized cell-therapy workflows. Investors watch strategic deals, platform adoption, and the company's ability to translate infrastructure into revenue.

## Landscape Position

Orgenesis occupies a niche infrastructure position within biotech. It is less of a classic drug stock and more of a platform-enablement story tied to cell therapy manufacturing.

## Future Catalysts

- Orgenesis’ catalysts are cell-therapy manufacturing, point-of-care platform execution, and any update that clarifies how the company is monetizing its assets. The story is still mostly about platform commercialization.

## Recent News
- 2024-11-13 13:00 EST — [Orgenesis Provides Third Quarter 2024 Business Update](https://biopharmsignal.com/news/ORGS/orgenesis-provides-third-quarter-2024-business-update-0a0b7433) — Source: Orgenesis
- 2024-10-21 12:00 EST — [Orgenesis Commences Trading on OTCQX® Best Market](https://biopharmsignal.com/news/ORGS/orgenesis-commences-trading-on-otcqx-best-market-e1e5be9a) — Source: Orgenesis
- 2024-09-23 11:00 EST — [Orgenesis Announces Reverse Stock Split](https://biopharmsignal.com/news/ORGS/orgenesis-announces-reverse-stock-split-ecc39494) — Source: Orgenesis
- 2024-08-29 12:30 EST — [Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia](https://biopharmsignal.com/news/ORGS/orgenesis-announces-positive-results-from-a-real-world-study-of-org-101-car-t-th-87fd0475) — Source: Orgenesis
- 2024-08-14 12:30 EST — [Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally](https://biopharmsignal.com/news/ORGS/orgenesis-announces-strategic-partnership-with-harley-street-healthcare-group-to-fdf35587) — Source: Orgenesis